ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Myhre, B.
Right arrow Articles by Ukkestad, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Myhre, B.
Right arrow Articles by Ukkestad, T.
Annals of Clinical and Laboratory Science, Vol 24, Issue 1, 76-83
Copyright © 1994 by Association of Clinical Scientists

Articles

The correlations of surrogate markers with anti-hepatitis C virus and other disease markers

BA Myhre, L Jiminez, P Shitabata, and TS Ukkestad

Testing of donors' sera for the level of alanine aminotransferase (ALT) and the presence of hepatitis B core antibody (anti-HBc) has been required since 1986 as "surrogate" tests for non-A, non-B post transfusion hepatitis (NANB-PTH). With the availability of a test for the antibody to hepatitis C virus (HCV), the need for these two tests and their impact on one hospital are reviewed. Precisely 12.3 percent of the donors were excluded for reactivity to surrogate disease markers but no reactivity to "true" markers. The positive predictive values of these surrogate tests were low and comparable (varying from 7.4 percent to 30 percent). In view of the high rate of donor exclusion and the low rate of correlation with "true" disease markers, the need for these tests needs to be reassessed.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the Association of Clinical Scientists.